News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,462 Results
Type
Article (40285)
Company Profile (251)
Press Release (668916)
Multimedia
Podcasts (67)
Webinars (15)
Section
Business (204404)
Career Advice (2014)
Deals (35472)
Drug Delivery (99)
Drug Development (81209)
Employer Resources (172)
FDA (16291)
Job Trends (14907)
News (345771)
Policy (32656)
Tag
Academia (2557)
Accelerated approval (14)
Adcomms (23)
Allergies (107)
Alliances (49573)
ALS (124)
Alzheimer's disease (1510)
Antibody-drug conjugate (ADC) (166)
Approvals (16335)
Artificial intelligence (349)
Autoimmune disease (38)
Automation (23)
Bankruptcy (361)
Best Places to Work (11635)
BIOSECURE Act (19)
Biosimilars (132)
Biotechnology (174)
Bladder cancer (111)
Brain cancer (39)
Breast cancer (407)
Cancer (3264)
Cardiovascular disease (263)
Career advice (1688)
Career pathing (32)
CAR-T (202)
CDC (34)
Cell therapy (541)
Cervical cancer (27)
Clinical research (67414)
Collaboration (1163)
Company closure (4)
Compensation (828)
Complete response letters (35)
COVID-19 (2657)
CRISPR (66)
C-suite (461)
Cystic fibrosis (119)
Data (3615)
Decentralized trials (2)
Denatured (22)
Depression (77)
Diabetes (376)
Diagnostics (6482)
Digital health (27)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (160)
Drug pricing (135)
Drug shortages (28)
Duchenne muscular dystrophy (168)
Earnings (88526)
Editorial (43)
Employer branding (21)
Employer resources (148)
Events (114572)
Executive appointments (886)
FDA (18394)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1032)
Gene editing (146)
Generative AI (24)
Gene therapy (423)
GLP-1 (827)
Government (4566)
Grass and pollen (5)
Guidances (330)
Healthcare (18851)
HIV (42)
Huntington's disease (31)
IgA nephropathy (47)
Immunology and inflammation (180)
Immuno-oncology (12)
Indications (45)
Infectious disease (2848)
Inflammatory bowel disease (161)
Inflation Reduction Act (10)
Influenza (76)
Intellectual property (152)
Interviews (313)
IPO (16604)
IRA (48)
Job creations (3640)
Job search strategy (1424)
Kidney cancer (13)
Labor market (63)
Layoffs (518)
Leadership (21)
Legal (7934)
Liver cancer (83)
Longevity (11)
Lung cancer (474)
Lymphoma (242)
Machine learning (21)
Management (58)
Manufacturing (488)
MASH (106)
Medical device (13553)
Medtech (13570)
Mergers & acquisitions (19667)
Metabolic disorders (926)
Multiple sclerosis (109)
NASH (16)
Neurodegenerative disease (150)
Neuropsychiatric disorders (36)
Neuroscience (2305)
NextGen: Class of 2025 (6517)
Non-profit (4492)
Now hiring (53)
Obesity (456)
Opinion (227)
Ovarian cancer (110)
Pain (135)
Pancreatic cancer (140)
Parkinson's disease (198)
Partnered (24)
Patents (359)
Patient recruitment (252)
Peanut (51)
People (57985)
Pharmaceutical (62)
Pharmacy benefit managers (21)
Phase I (20980)
Phase II (29694)
Phase III (22096)
Pipeline (2356)
Policy (226)
Postmarket research (2564)
Preclinical (8938)
Press Release (64)
Prostate cancer (159)
Psychedelics (39)
Radiopharmaceuticals (255)
Rare diseases (513)
Real estate (5926)
Recruiting (66)
Regulatory (23075)
Reports (51)
Research institute (2333)
Resumes & cover letters (350)
Rett syndrome (11)
RNA editing (11)
RSV (55)
Schizophrenia (104)
Series A (166)
Series B (128)
Service/supplier (11)
Sickle cell disease (68)
Special edition (19)
Spinal muscular atrophy (148)
Sponsored (34)
Startups (3595)
State (2)
Stomach cancer (14)
Supply chain (84)
Tariffs (71)
The Weekly (43)
Vaccines (857)
Venture capital (59)
Weight loss (281)
Women's health (51)
Worklife (17)
Date
Today (59)
Last 7 days (426)
Last 30 days (2068)
Last 365 days (30919)
2025 (21345)
2024 (35217)
2023 (40077)
2022 (51176)
2021 (55710)
2020 (54083)
2019 (46539)
2018 (35023)
2017 (32112)
2016 (31481)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (724)
Alabama (69)
Alaska (7)
Arizona (256)
Arkansas (13)
Asia (38435)
Australia (6268)
California (8482)
Canada (2623)
China (764)
Colorado (354)
Connecticut (360)
Delaware (223)
Europe (82722)
Florida (1266)
Georgia (285)
Hawaii (2)
Idaho (60)
Illinois (677)
India (38)
Indiana (399)
Iowa (17)
Japan (257)
Kansas (114)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1127)
Massachusetts (6206)
Michigan (264)
Minnesota (503)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (97)
New Hampshire (68)
New Jersey (2318)
New Mexico (28)
New York (2305)
North Carolina (1181)
North Dakota (8)
Northern California (3845)
Ohio (259)
Oklahoma (16)
Oregon (35)
Pennsylvania (1796)
Puerto Rico (17)
Rhode Island (41)
South America (1098)
South Carolina (43)
South Dakota (1)
Southern California (3251)
Tennessee (138)
Texas (1303)
United States (30895)
Utah (251)
Virginia (209)
Washington D.C. (74)
Washington State (701)
West Virginia (4)
Wisconsin (71)
709,462 Results for "veru inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough?
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy alone but investors await more data.
January 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
August 12, 2025
·
3 min read
Press Releases
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
July 23, 2025
·
11 min read
Press Releases
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
August 12, 2025
·
18 min read
Press Releases
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
August 6, 2025
·
8 min read
Press Releases
Veru to Participate in the Virtual BTIG Obesity Health Forum
June 12, 2025
·
10 min read
Press Releases
Veru Participates in a Virtual Investor KOL Connect Segment
May 8, 2025
·
6 min read
Press Releases
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
May 1, 2025
·
14 min read
BioMidwest
Veru to Present at the 2024 Jefferies Global Healthcare Conference
Veru Inc. announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am – 11:25 am ET.
May 22, 2024
·
10 min read
Press Releases
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
May 8, 2025
·
23 min read
1 of 70,947
Next
